News | July 06, 2022
Wacker to expand mRNA-based actives capacity at Halle, Germany
Company is investing more than €100 million in the expansion of the Halle site
Company is investing more than €100 million in the expansion of the Halle site
_256_384.jpg){kind=logo}
Meets the growing need for US-based API solubility and bioavailability enhancement services
Addition of Pepscan with its peptide discovery, lead optimization and GMP manufacturing capabilities provides end-to-end offering to Biosynth Carbosynth’s peptide customers.
This facility will produce higher efficacy products that enjoy greater acceptance and enhanced profit marginsg
The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity
Bringing next-gen cannabinoid therapeutics to cancer patients
The ground floor of the formulation development laboratory is focused on solid orals, the first floor on injections, and the second floor houses the analytical lab
The new program includes upstream and downstream process development and large-scale GMP production.
The production and supply in Canada are designed to address the growing need for no-carrier-added Lutetium-177 (n.c.a. Lu-177) in North America
The company has launched indigenously produced Dual Chamber Bags of global standards in India at a pocket-friendly price
Subscribe To Our Newsletter & Stay Updated
